Jylamvo
Jylamvo - Europe
Jylamvo is an oral solution that contains 2 mg/ml of methotrexate. The product was granted a European Marketing Authorisation by the European Medicines Agency (EMA) on 29 March 2017.
Jylamvo is authorised for use in the following indications:
In rheumatological and dermatological diseases
-
Active rheumatoid arthritis in adult patients.
-
Polyarthritic forms of active, severe juvenile idiopathic arthritis (JIA) in adolescents and children aged 3 years and over when the response to non‑steroidal anti‑inflammatory drugs (NSAIDs) has been inadequate.
-
Severe, treatment‑refractory, disabling psoriasis which does not respond sufficiently to other forms of treatment such as phototherapy, psoralen and ultraviolet A radiation (PUVA) therapy and retinoids, and severe psoriatic arthritis in adult patients.
In oncology
-
Maintenance treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children aged 3 years and over
For Medical Information, Product Complaints, Adverse Event Reporting, please click here.
For Sales inquires, please click here.
Educational Package for Healthcare Professionals, please click here.